Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

29 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

Scatter radiation during mammography does not increase risk of cancer

The radiation dose to areas of the body near the breast during mammography is negligible, or very low, and does not result in an increased risk of cancer, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

27 Nov 2012

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

8 Nov 2012

Protocol allows researchers to generate functional thyroid tissue from stem cells

The generation of functional thyroid tissue from stem cells could allow the treatment of patients, which suffer from thyroid hormone deficiency due to defective function, or abnormal development of the thyroid gland.

12 Oct 2012

Adolescent and young cancer cost barriers: an interview with Anne Kirchhoff

According to the National Cancer Institute, almost 70,000 people ages 15-39 are diagnosed with cancer each year in the United States. Cancers in this adolescent and young adult (AYA) population differ quite a bit across this age span.

3 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

Novel genetic tools may shed new light in papillary thyroid carcinoma research

Next-generation sequencing analyses of the follicular variant of papillary thyroid carcinoma may elucidate the biological underpinnings and clinical behavior of an increasingly common disease, according to data presented at the 82nd ATA Annual Meeting in Québec City, Québec, Canada.

24 Sep 2012

Age 65 and above may be more accurate marker for prognosis of papillary thyroid cancer

Although age 45 is used to establish staging in well-differentiated papillary thyroid cancer using the American Joint Committee on Cancer and the International Union Against Cancer TNM Classification of Malignant Tumors (TNM) staging system, a new study presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada, suggests that > 65 may be a more accurate age marker for prognosis.

24 Sep 2012

Disparities prevail in surgical management of well-differentiated thyroid cancer

A spectrum of disparities exist in the surgical management of well-differentiated thyroid cancer, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

New mouse models can help scientists study SECISBP2 syndrome

New mouse models can help scientists study a rare disease, called SECISBP2 syndrome, that causes abnormal thyroid hormone metabolism, delayed bone maturation, as well as other abnormal characteristics that vary by individual, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

Genome-wide epigenomic screening can pinpoint thyroid disease-associated variants

Genome-wide epigenomic screening can pinpoint disease-associated variants and identify novel genetic-epigenetic interactions in autoimmune thyroid diseases, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

Radioactive iodine should only be used in treatment of some patients with papillary thyroid cancer

Radioactive iodine should only be used in the treatment of some patients with papillary thyroid cancer, according to data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

New mouse models can help scientists study MCT8 deficiency

New mouse models can help scientists study MCT8 deficiency, an inherited genetic disorder affecting children, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

21 Sep 2012

Exposures to perchlorate could reduce thyroidal iodine uptake in women and fetuses

Exposures to perchlorate (ClO4), a compound found at low levels in the environment, and thiocyanate (SCN), a compound found in cigarette smoke and some foods, is unlikely to alter thyroid function in pregnant women and fetuses, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

21 Sep 2012

Subclinical hyperthyroidism does not lead to cardiovascular and total mortality

Subclinical hyperthyroidism is not associated with overall or cardiovascular mortality, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

21 Sep 2012

Radioactive iodine may predispose young thyroid cancer patients to second primary malignancies

Children and young adult thyroid cancer patients who are treated with radioactive iodine have an elevated risk of developing a second primary malignancy, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.

21 Sep 2012

Thyroid journal publishes new ATA guidelines for diagnosis and treatment of hypothyroidism

The American Thyroid Association (ATA) today announced that new clinical practice guidelines for the diagnosis and treatment of hypothyroidism are published in the current issue of Thyroid.

21 Sep 2012

Thyroid cancer among people with low SES is diagnosed at a more advanced stage

Thyroid cancer among people with lower socioeconomic status is diagnosed at a more advanced stage, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

21 Sep 2012

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

Scatter radiation during mammography does not increase risk of cancer

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

Protocol allows researchers to generate functional thyroid tissue from stem cells

Adolescent and young cancer cost barriers: an interview with Anne Kirchhoff

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Novel genetic tools may shed new light in papillary thyroid carcinoma research

Age 65 and above may be more accurate marker for prognosis of papillary thyroid cancer

Disparities prevail in surgical management of well-differentiated thyroid cancer

New mouse models can help scientists study SECISBP2 syndrome

Genome-wide epigenomic screening can pinpoint thyroid disease-associated variants

Radioactive iodine should only be used in treatment of some patients with papillary thyroid cancer

New mouse models can help scientists study MCT8 deficiency

Exposures to perchlorate could reduce thyroidal iodine uptake in women and fetuses

Subclinical hyperthyroidism does not lead to cardiovascular and total mortality

Radioactive iodine may predispose young thyroid cancer patients to second primary malignancies

Thyroid journal publishes new ATA guidelines for diagnosis and treatment of hypothyroidism

Thyroid cancer among people with low SES is diagnosed at a more advanced stage

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in